Smoking status during first‐line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A case–control matched analysis from a large multicenter study

Abstract

Among metastatic NSCLC patients with PD-L1 expression ≥50% receiving first-line pembrolizumab, current/former smokers experienced improved PFS and OS. On the contrary, worse outcomes were reported among current/former smokers receiving first-line chemotherapy.